Skip to main content
Premium Trial:

Request an Annual Quote

Biofield Licenses Rights to HPV Dx from ValiRx

NEW YORK (GenomeWeb News) – Biofield today said that it has licensed exclusive worldwide distribution rights, outside of Belgium, to ValiRx's human papillomavirus diagnostic test as well as its HyperGenomics and Nucleosomics cancer diagnostic products.

The products are being developed by ValiBio, a Belgian joint venture between the UK's ValiRx and the Institut de Pathologie et de Genetique, which houses ValiBio's operations.

The HPV test is being developed to detect infection by any of the known 15 high-risk HPV subtypes, according to ValiRx's website. The HyperGenomics platform includes differential diagnostic tests being developed for a variety of cancers, and the Nucleosomics platform includes non-invasive tests for detecting early cancer through epigenetic signal changes.

Philadelphia-based Biofield is developing its own diagnostic system for the early detection of breast cancer. The firm said that it aims to generate revenue from sales of this system to customers in foreign markets while acquiring other non-invasive detection and prevention technologies.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.